Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Shares Bought by Barclays PLC

Barclays PLC boosted its stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 349.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 184,189 shares of the company’s stock after buying an additional 143,184 shares during the period. Barclays PLC owned 0.07% of Maravai LifeSciences worth $1,531,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp boosted its stake in Maravai LifeSciences by 30.1% during the second quarter. Bank of New York Mellon Corp now owns 506,413 shares of the company’s stock worth $3,626,000 after buying an additional 117,120 shares during the last quarter. Dragoneer Investment Group LLC acquired a new position in Maravai LifeSciences during the second quarter worth $5,373,000. Royce & Associates LP boosted its stake in Maravai LifeSciences by 130.4% during the third quarter. Royce & Associates LP now owns 908,778 shares of the company’s stock worth $7,552,000 after buying an additional 514,332 shares during the last quarter. Mackenzie Financial Corp boosted its stake in Maravai LifeSciences by 16.8% during the second quarter. Mackenzie Financial Corp now owns 5,860,641 shares of the company’s stock worth $41,962,000 after buying an additional 844,325 shares during the last quarter. Finally, Systematic Financial Management LP lifted its stake in shares of Maravai LifeSciences by 14.7% in the 3rd quarter. Systematic Financial Management LP now owns 1,612,161 shares of the company’s stock valued at $13,397,000 after purchasing an additional 206,499 shares during the last quarter. Institutional investors and hedge funds own 50.25% of the company’s stock.

Maravai LifeSciences Price Performance

MRVI stock opened at $4.85 on Monday. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89. The company has a market capitalization of $1.22 billion, a PE ratio of -2.96 and a beta of -0.07. Maravai LifeSciences Holdings, Inc. has a 12-month low of $4.28 and a 12-month high of $11.56. The business’s fifty day moving average price is $5.65 and its 200 day moving average price is $7.41.

Insider Activity at Maravai LifeSciences

In related news, insider Carl Hull purchased 175,000 shares of the business’s stock in a transaction on Monday, November 11th. The shares were bought at an average price of $5.64 per share, for a total transaction of $987,000.00. Following the acquisition, the insider now directly owns 175,000 shares in the company, valued at $987,000. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.63% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Royal Bank of Canada decreased their price target on Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating on the stock in a research note on Friday, November 8th. Wolfe Research assumed coverage on Maravai LifeSciences in a research note on Thursday, November 14th. They issued a “peer perform” rating on the stock. The Goldman Sachs Group lowered Maravai LifeSciences from a “neutral” rating to a “sell” rating and decreased their price target for the company from $7.00 to $4.25 in a research note on Thursday, December 5th. William Blair reaffirmed a “market perform” rating on shares of Maravai LifeSciences in a research note on Friday, November 8th. Finally, Guggenheim assumed coverage on Maravai LifeSciences in a research note on Thursday, December 19th. They issued a “neutral” rating on the stock. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Maravai LifeSciences presently has a consensus rating of “Hold” and an average price target of $10.28.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.